Shivalinga Kollea and
Sanjay Batra*ab
aMedicinal and Process Chemistry Division, CSIR-Central Drug Research Institute, Sector 10, Jankipuram Extension, Sitapur Road, Lucknow-226031, UP, India. E-mail: batra_san@yahoo.co.uk; s_batra@cdri.res.in
bAcademy for Scientific and Innovative Research, New Delhi-110025, India
First published on 18th May 2016
A palladium-catalysed β-carboline directed decarboxylative acylation of ortho-C(sp2)–H of the aryl ring of aryl(β-carbolin-1-yl)methanones using α-oxocarboxylic acid as the acyl ion equivalent to form (2-aroylaryl)(β-carbolin-2-yl)methanones is described. The utility of these products for preparing β-carboline-tethered phthalazine systems is also demonstrated.
β-Carboline, a privileged scaffold, is core unit of several natural alkaloids and bioactive compounds endowed with diverse pharmacological properties.18 The first example of β-carboline-directed ruthenium-catalyzed arylation was reported by Gandhi et al.19 Subsequently we reported Pd(OAc)2-catalysed regioselective alkoxylation (C–O bond formation) of aryl(β-carbolin-1-yl)methanones employing β-carboline directed ortho-C(sp2)–H activation of an aryl ring under oxidative conditions.20 Continuing with our efforts to study the scope of β-carboline directed C(sp2)–H activation for installing various functional groups, we now disclose a Pd-catalysed β-carboline directed decarboxylative acylation using α-oxocarboxylic acid as the acyl ion source to form (2-aroylaryl)(β-carbolin-2-yl)methanones.
| Entry | Pd source (mol%) | Oxidant (equiv.) | Solvent | Yieldb (%) |
|---|---|---|---|---|
| a All reactions were performed using 1a (0.1 g, 0.367 mmol) and 2a (0.55 mmol) in a solvent (2 mL).b Isolated yield after column chromatography.c Reaction at 60 °C.d Reaction at 100 °C. | ||||
| 1 | Pd(OAc)2 (10) | (NH4)2S2O8 (1) | DCE | 72 |
| 2 | Pd(OAc)2 (10) | (NH4)2S2O8 (1) | Dioxane | 46 |
| 3 | Pd(OAc)2 (10) | (NH4)2S2O8 (1) | THF | 42 |
| 4 | Pd(OAc)2 (10) | (NH4)2S2O8 (1) | Diglyme | 54 |
| 5 | Pd(OAc)2 (10) | Na2S2O8 (1) | DCE | 73 |
| 6 | Pd(OAc)2 (10) | K2S2O8 (1) | DCE | 74 |
| 7 | Pd(OAc)2 (10) | PhI(OAc)2 (1) | DCE | 68 |
| 8 | Pd(OAc)2 (10) | Cu(OAc)2 (1) | DCE | 61 |
| 9 | Pd(OAc)2 (10) | K2S2O8 (2) | DCE | 82 |
| 10 | Pd(OAc)2 (10) | K2S2O8 (3) | DCE | 83 |
| 11 | Pd(OAc)2 (5) | K2S2O8 (2) | DCE | 55 |
| 12 | — | K2S2O8 (2) | DCE | 0 |
| 13 | PdCl2 (10) | K2S2O8 (2) | DCE | 52 |
| 14 | Pd(TFA)2 (10) | K2S2O8 (2) | DCE | 80 |
| 15c | Pd(OAc)2 (10) | K2S2O8 (2) | DCE | 71 |
| 16d | Pd(OAc)2 (10) | K2S2O8 (2) | DCE | 81 |
With the optimized conditions in hands, we assessed the scope of the protocol with different α-oxocarboxylic acids and β-carbolines. Initially a variety of α-oxocarboxylic acids (2b–i) were investigated for their reactions with phenyl(β-carbolin-1-yl)methanone (1a) (Scheme 1). α-Oxocarboxylic acids (2b–f) bearing phenyl ring with electron donating or electron withdrawing groups reacted with 1a affording the corresponding products 3ab–3af in good to excellent yields. Treating α-oxocarboxylic acid bearing thiophene moiety (2g) with 1a gave the product 3ag in 77% yield. However, aliphatic α-oxocarboxylic acids (2h, i) failed to react with 1a to yield the respective products 3ah, 3ai.
![]() | ||
| Scheme 1 Scope of the protocol with different α-oxocarboxylic acids. All reactions were performed using 1a (0.5 mmol) and 2b–i (0.75 mmol) in 3 mL of solvent. | ||
Next the reaction of 2a was investigated with different starting aryl(β-carbolin-1-yl)methanones (1b–p) (Scheme 2). It was observed that the position of substituents on the aryl ring has direct bearing on the formation of the product. When the aryl ring was 3- or 4-substituted phenyl (1b–h), the products 3ba–3ha were isolated in 76–87% yields. Interestingly, for the 3-substituted phenyl ring carrying substrate (1g, h) the reaction was found to be regioselective to yield 3ga, 3ha. However, substrates 1i, j containing phenyl ring with ortho-substitution failed to give the required products 3ia, 3ja. Perhaps, this failure is attributed to the steric hindrance due to the presence of substituent at the ortho-position in the phenyl ring. Further, the failure of reaction with 1j inferred that the possibility of diacylation is ruled out. Even the heteroaryl(β-carbolin-1-yl)methanones 1k and 1l bearing thiophene and benzofuran units were found to undergo decarboxylative acylation with 2a affording the corresponding products 3ka and 3la in 72% and 74% yields, respectively. Substrates 1m, 1n, 1o, and 1p bearing bromo and chloro substitutions at 6-position and methyl ester at 3-position of the β-carboline unit, were also investigated to obtain respective products 3ma, 3na, 3oa and 3pa in excellent yields. Finally the scope of reaction was evaluated with phenyl(pyridin-2-yl)methanone 1q and it too reacted with 2a to give acylated product 3qa in 79% yield.
![]() | ||
| Scheme 2 Scope of the protocol with different aryl(β-carbolin-2-yl)methanones. All reactions were performed using 1b–n (0.5 mmol) and 2a (0.75 mmol) in 3 mL of solvent. | ||
As already reported, mechanism wise the pyridine ring of the β-carboline unit undergo chelation with the Pd-catalyst followed by coupling reaction as delineated in Scheme 3. Here too, for negating the role of carbonyl for the C–H functionalization,21 we carried out reaction of (9H-carbazol-1-yl)(phenyl)methanone 4 under the optimized conditions (Scheme 4). It was found that the reaction was unsuccessful and 4 was recovered unreacted. This ascertained that the pyridine ring was involved in chelation with palladium.
Finally, to demonstrate the utility of the isolated diaroyl-products belonging to 3, a randomly selected set of substrates were treated with hydrazine hydrochloride in the presence of NaHCO3 in ethanol as medium to prepare β-carboline tethered phthalazine derivatives 5 in 82–92% yields (Scheme 5). It may be noted the phthalazine pendant at the 3-position of β-carboline was prepared via Suzuki coupling between 3-chloro-β-carboline and phthalazine-1-boronic acid.22
:
10, v/v) as eluent to obtain corresponding product 3.
:
EtOAc, 8
:
2, v/v). IR (KBr) νmax: 769, 1168, 1220, 1455, 1580, 1651, 3022, 3431 cm−1. 1H NMR (400 MHz, CDCl3): δ (ppm) = 7.22 (t, J = 7.7 Hz, 1H), 7.29 (t, J = 7.7 Hz, 2H), 7.39 (t, J = 7.3 Hz, 1H), 7.46–7.56 (m, 4H), 7.61–7.64 (m, 1H), 7.77 (d, J = 7.5 Hz, 2H), 7.86–7.88 (m, 2H), 7.99 (d, J = 7.9 Hz, 1H), 8.07 (d, J = 4.9 Hz, 1H), 10.22 (s, 1H). 13C NMR (100 MHz, CDCl3): δ (ppm) = 112.1, 118.7, 120.8, 121.9, 128.2, 129.2, 129.4, 130.1, 130.3, 131.1, 131.6, 132.6, 135.8, 136.4, 137.5, 138.1, 139.5, 140.9, 141.3, 196.6, 198.1. MS (ESI+) m/z = 377.1. ESI-HRMS calculated for C25H16N2O2 [MH]+: 377.1290, found: 377.1292.
:
EtOAc, 8
:
2, v/v). IR (KBr) νmax: 758, 1185, 1258, 1458, 1586, 1661, 3058, 3434 cm−1. 1H NMR (400 MHz, CDCl3): δ (ppm) = 2.25 (s, 3H), 7.08 (d, J = 7.9 Hz, 2H), 7.22 (t, J = 7.0 Hz, 1H), 7.45–7.49 (m, 2H), 7.54 (t, J = 6.9 Hz, 2H), 7.59–7.62 (m, 1H), 7.65 (d, J = 8.1 Hz, 2H), 7.87 (d, J = 5.5 Hz, 2H), 8.00 (d, J = 7.9 Hz, 1H), 8.09 (d, J = 4.9 Hz, 1H), 10.21 (s, 1H). 13C NMR (100 MHz, CDCl3): δ (ppm) = 21.7, 112.0, 118.6, 120.8, 121.8, 128.9, 129.1, 129.3, 130.1, 130.3, 130.4, 131.9, 131.5, 134.9, 135.8, 136.4, 138.1, 139.4, 141.2, 143.4, 196.3, 198.1. MS (ESI+) m/z = 391.2. ESI-HRMS calculated for C26H18N2O2 [MH]+: 391.1447, found: 391.1450.
:
EtOAc, 8
:
2, v/v). IR (KBr) νmax: 772, 1185, 1225, 1456, 1591, 1659, 3013, 3433 cm−1. 1H NMR (400 MHz, CDCl3): δ (ppm) = 7.21–7.25 (m, 1H), 7.29 (d, J = 8.4 Hz, 2H), 7.47–7.56 (m, 4H), 7.62–7.65 (m, 1H), 7.73 (d, J = 8.4 Hz, 2H), 7.87–7.89 (m, 2H), 7.99–8.04 (m, 2H), 10.24 (s, 1H). 13C NMR (100 MHz, CDCl3): δ (ppm) = 112.1, 118.8, 120.8, 120.9, 121.9, 128.6, 128.8, 129.4, 130.2, 130.5, 131.3, 131.7, 135.6, 135.8, 136.5, 138.1, 139.1, 139.3, 140.7, 141.3, 195.4, 197.8. MS (ESI+) m/z = 411.1. ESI-HRMS calculated for C25H15ClN2O2 [MH]+: 411.0900, found: 411.0904.
:
EtOAc, 8
:
2, v/v). IR (KBr) νmax: 756, 1125, 1285, 1425, 1587, 1659, 3052, 3435 cm−1. 1H NMR (400 MHz, CDCl3): δ (ppm) = 7.22–7.26 (m, 1H), 7.49–7.54 (m, 4H), 7.59 (t, J = 7.6 Hz, 1H), 7.69 (t, J = 7.5 Hz, 1H), 7.88 (d, J = 4.9 Hz, 1H), 7.93 (d, J = 7.6 Hz, 1H), 7.99–8.03 (m, 2H), 8.10 (d, J = 7.7 Hz, 1H), 8.26 (dd, J1 = 8.2 Hz, J2 = 1.2 Hz, 1H), 8.64 (s, 1H), 10.23 (s, 1H). 13C NMR (100 MHz, DMSO-d6): δ (ppm) = 113.5, 119.6, 120.2, 120.8, 122.3, 124.4, 127.6, 128.8, 129.6, 130.7, 130.8, 131.5, 132.1, 135.4, 135.6, 136.1, 137.5, 138.5, 139.5, 139.8, 142.3, 148.0, 194.5, 196.4. MS (ESI+) m/z = 422.1. ESI-HRMS calculated for C25H15N3O4 [MH]+: 422.1141, found: 422.1144.
:
EtOAc, 8
:
2, v/v). IR (KBr) νmax: 726, 1025, 1155, 1224, 1455, 1581, 1649, 3026, 3432 cm−1. 1H NMR (400 MHz, CDCl3): δ (ppm) = 5.78 (s, 2H), 6.67 (d, J = 8.1 Hz, 1H), 7.15 (d, J = 1.3 Hz, 1H), 7.22–7.25 (m, 1H), 7.31 (dd, J1 = 8.1 Hz, J2 = 1.4 Hz, 1H), 7.47–7.64 (m, 5H), 7.88 (d, J = 7.5 Hz, 1H), 7.92 (d, J = 4.9 Hz, 1H), 8.03 (d, J = 7.8 Hz, 1H), 8.15 (d, J = 4.9 Hz, 1H), 10.18 (s, 1H). 13C NMR (100 MHz, CDCl3): δ (ppm) = 101.8, 107.5, 109.4, 112.1, 118.7, 120.8, 120.8, 121.9, 127.0, 129.0, 129.3, 130.3, 130.4, 130.8, 131.5, 132.3, 135.9, 136.4, 138.2, 139.3, 141.1, 141.2, 147.8, 151.5, 194.9, 197.9. MS (ESI+) m/z = 421.1. ESI-HRMS calculated for C26H16N2O4 [MH]+: 421.1188, found: 421.1191.
:
EtOAc, 8
:
2, v/v). IR (KBr) νmax: 725, 1185, 1221, 1432, 1592, 1655, 3021, 3434 cm−1. 1H NMR (400 MHz, CDCl3): δ (ppm) = 2.27 (s, 3H), 7.09–7.15 (m, 2H), 7.22–7.26 (m, 2H), 7.47 (dd, J1 = 6.6 Hz, J2 = 1.3 Hz, 2H), 7.52 (d, J = 3.6 Hz, 2H), 7.59–7.65 (m, 2H), 7.71 (d, J = 7.1 Hz, 1H), 7.93 (d, J = 4.9 Hz, 1H), 8.04 (d, J = 7.8 Hz, 1H), 8.23 (d, J = 4.9 Hz, 1H), 10.29 (s, 1H). 13C NMR (100 MHz, CDCl3): δ (ppm) = 112.13, 118.6, 120.8, 120.9, 121.9, 125.1, 129.3, 129.4, 129.8, 130.3, 130.8, 131.1, 131.2, 131.6, 132.0, 136.1, 136.3, 137.5, 138.3, 138.6, 140.5, 141.1, 141.3, 198.2, 199.5. MS (ESI+) m/z = 391.1. ESI-HRMS calculated for C26H18N2O2 [MH]+: 391.1447, found: 391.1450.
:
EtOAc, 8
:
2, v/v). IR (KBr) νmax: 758, 1058, 1152, 1282, 1425, 1596, 1658, 3025, 3432 cm−1. 1H NMR (400 MHz, CDCl3): δ (ppm) = 7.99 (d, J = 4.0 Hz, 1H), 7.23 (t, J = 6.9 Hz, 1H), 7.49–7.63 (m, 6H), 7.74–7.77 (m, 1H), 7.88 (d, J = 7.5 Hz, 1H), 7.91 (d, J = 4.7 Hz, 1H), 8.02 (d, J = 7.6 Hz, 1H), 8.11 (d, J = 4.6 Hz, 1H), 10.25 (s, 1H). 13C NMR (100 MHz, CDCl3): δ (ppm) = 112.2, 118.8, 120.9, 121.9, 127.9, 128.7, 129.4, 130.5, 130.6, 131.1, 131.7, 133.6, 134.2, 134.9, 135.7, 136.5, 138.1, 139.1, 140.7, 141.3, 144.2, 188.3, 197.8. MS (ESI+) m/z = 383.1. ESI-HRMS calculated for C23H14N2O2S [MH]+: 383.0854, found: 383.0852.
:
EtOAc, 8
:
2, v/v). IR (KBr) νmax: 778, 1159, 1222, 1412, 1591, 1652, 3015, 3436 cm−1. 1H NMR (400 MHz, CDCl3): δ (ppm) = 2.41 (s, 3H), 7.20–7.29 (m, 3H), 7.36–7.52 (m, 5H), 7.74 (d, J = 1.4 Hz, 1H), 7.76 (d, J = 1.2 Hz, 1H), 7.83 (d, J = 7.8 Hz, 1H), 7.88 (dd, J1 = 4.9 Hz, J2 = 0.5 Hz, 1H), 7.99–8.02 (m, 1H), 8.11 (d, J = 4.9 Hz, 1H), 10.19 (s, 1H). 13C NMR (100 MHz, CDCl3): δ (ppm) = 21.6, 112.0, 118.6, 120.8, 121.8, 128.2, 129.3, 129.7, 130.1, 130.7, 131.5, 132.5, 135.9, 136.4, 136.5, 137.6, 138.0, 140.9, 141.2, 141.2, 196.8, 197.6. MS (ESI+) m/z = 391.1. ESI-HRMS calculated for C26H18N2O2 [MH]+: 391.1447, found: 391.1445.
:
EtOAc, 8
:
2, v/v). IR (KBr) νmax: 758, 1187, 1281, 1421, 1589, 1660, 3033, 3432 cm−1. 1H NMR (400 MHz, CDCl3): δ (ppm) = 3.84 (s, 3H), 7.04 (d, J = 2.5 Hz, 1H), 7.10 (dd, J1 = 8.6 Hz, J2 = 2.6 Hz, 1H), 7.16–7.28 (m, 3H), 7.34–7.38 (m, 1H), 7.43–7.51 (m, 2H), 7.75 (d, J = 1.4 Hz, 1H), 7.77 (d, J = 0.8 Hz, 1H), 7.89 (d, J = 4.9 Hz, 1H), 8.01 (d, J = 7.8 Hz, 1H), 8.08 (d, J = 8.5 Hz, 1H), 8.15 (d, J = 4.9 Hz, 1H), 10.15 (s, 1H). 13C NMR (100 MHz, DMSO-d6): δ (ppm) = 56.3, 113.5, 114.7, 115.3, 119.2, 120.3, 120.7, 122.2, 128.8, 129.4, 130.0, 131.2, 131.3, 133.4, 133.8, 135.6, 136.3, 137.1, 137.4, 142.2, 143.5, 161.3, 194.7, 195.9. MS (ESI+) m/z = 407.1. ESI-HRMS calculated for C26H18N2O3 [MH]+: 407.1396, found: 407.1395.
:
EtOAc, 8
:
2, v/v). IR (KBr) νmax: 660, 773, 1155, 1234, 1442, 1575, 1653, 3052, 3436 cm−1. 1H NMR (400 MHz, CDCl3): δ (ppm) = 7.22–7.26 (m, 1H), 7.29–7.35 (m, 3H), 7.38–7.42 (m, 3H), 7.47–7.52 (m, 2H), 7.56 (s, 1H), 7.58 (d, J = 1.3 Hz, 1H), 7.75 (d, J = 1.6 Hz, 1H), 7.80 (d, J = 1.3 Hz, 1H), 7.82–7.85 (m, 2H), 7.89 (d, J = 4.9 Hz, 1H), 7.99–8.03 (m, 2H), 8.11 (d, J = 4.9 Hz, 1H), 10.29 (s, 1H). 13C NMR (100 MHz, CDCl3): δ (ppm) = 112.1, 118.7, 120.8, 120.9, 121.9, 127.5, 127.8, 128.3, 128.4, 129.2, 129.4, 129.4, 130.3, 131.2, 131.6, 132.7, 135.8, 136.5, 137.4, 137.9, 138.1, 139.7, 141.2, 141.8, 143.4, 196.6, 197.5. MS (ESI+) m/z = 453.2. ESI-HRMS calculated for C31H20N2O2 [MH]+: 453.1603, found: 453.1605.
:
EtOAc, 8
:
2, v/v). IR (KBr) νmax: 755, 1147, 1287, 1467, 1588, 1649, 3032, 3434 cm−1. 1H NMR (400 MHz, CDCl3): δ (ppm) = 7.31–7.35 (m, 1H), 7.42 (t, J = 7.8 Hz, 2H), 7.51–7.54 (m, 1H), 7.56–7.66 (m, 3H), 7.77 (d, J = 1.6 Hz, 1H), 7.84–7.90 (m, 3H), 7.99 (d, J = 8.0 Hz, 1H), 8.11 (d, J = 7.9 Hz, 1H), 8.17 (d, J = 4.9 Hz, 1H), 10.27 (s, 1H). 13C NMR (100 MHz, CDCl3): δ (ppm) = 112.1, 118.9, 120.8, 120.9, 121.9, 124.9, 128.4, 129.5, 130.2, 131.8, 132.1, 132.6, 133.0, 133.9, 135.4, 136.5, 136.8, 137.9, 138.1, 141.3, 142.8, 195.0, 196.7. MS (ESI+) m/z = 455.0. ESI-HRMS calculated for C25H15BrN2O2 [MH]+: 455.0395, found: 455.0392.
:
EtOAc, 8
:
2, v/v). IR (KBr) νmax: 669, 771, 1157, 1216, 1403, 1599, 1654, 3019, 3435 cm−1. 1H NMR (400 MHz, CDCl3): δ (ppm) = 7.22–7.26 (m, 1H), 7.32 (t, J = 7.8 Hz, 2H), 7.43 (t, J = 7.5 Hz, 1H), 7.46–7.52 (m, 3H), 7.59 (dd, J1 = 8.2 Hz, J2 = 2.0 Hz, 1H), 7.76 (d, J = 7.2 Hz, 2H), 7.86–7.89 (m, 2H), 8.01 (d, J = 7.8 Hz, 1H), 8.07 (d, J = 4.9 Hz, 1H), 10.17 (s, 1H). 13C NMR (100 MHz, CDCl3): δ (ppm) = 112.1, 118.9, 120.8, 120.9, 121.9, 128.4, 128.9, 129.5, 130.2, 130.9, 131.7, 131.9, 133.0, 135.4, 136.5, 136.7, 136.9, 137.5, 138.1, 141.2, 142.7, 195.2, 196.6. MS (ESI+) m/z = 411.1. ESI-HRMS calculated for C25H15ClN2O2 [MH]+: 411.0900, found: 411.0904.
:
EtOAc, 8
:
2, v/v). IR (KBr) νmax: 799, 1185, 1225, 1324, 1434, 1579, 1664, 3032, 3434 cm−1. 1H NMR (400 MHz, CDCl3): δ (ppm) = 3.87 (s, 3H), 6.99 (dd, J1 = 8.6 Hz, J2 = 2.6 Hz, 1H), 7.21–7.25 (m, 1H), 7.27–7.31 (m, 3H), 7.39 (t, J = 7.3 Hz, 1H), 7.50–7.55 (m, 3H), 7.71 (d, J = 7.2 Hz, 2H), 7.88 (d, J = 4.9 Hz, 1H), 8.01 (d, J = 7.8 Hz, 1H), 8.11 (d, J = 4.9 Hz, 1H), 10.25 (s, 1H). 13C NMR (100 MHz, CDCl3): δ (ppm) = 55.8, 112.1, 114.8, 115.3, 118.6, 120.8, 120.8, 121.8, 128.1, 129.3, 130.1, 131.6, 131.9, 132.2, 132.9, 135.9, 136.2, 137.9, 138.2, 141.3, 142.4, 162.2, 195.7, 198.6. MS (ESI+) m/z = 407.1. ESI-HRMS calculated for C26H18N2O3 [MH]+: 407.1396, found: 407.1399.
:
2, v/v). IR (KBr) νmax: 745, 1057, 1285, 1423, 1586, 1650, 3045, 3436 cm−1. 1H NMR (400 MHz, CDCl3): δ (ppm) = 7.22 (t, J = 7.7 Hz, 1H), 7.28–7.34 (m, 2H), 7.42 (t, J = 7.2 Hz, 1H), 7.48–7.54 (m, 4H), 7.74 (d, J = 7.6 Hz, 2H), 7.82 (s, 1H), 7.88 (d, J = 4.8 Hz, 1H), 8.01 (d, J = 7.8 Hz, 1H), 8.06 (d, J = 4.9 Hz, 1H), 10.19 (s, 1H). 13C NMR (100 MHz, CDCl3): δ (ppm) = 112.1, 118.9, 120.7, 120.9, 121.9, 128.3, 129.5, 129.9, 130.2, 130.4, 130.5, 131.7, 132.8, 135.2, 136.4, 137.2, 137.6, 138.2, 139.2, 141.2, 141.3, 195.6, 196.6. MS (ESI+) m/z = 411.1. ESI-HRMS calculated for C25H15ClN2O2 [MH]+: 411.0900, found: 411.0901.
:
EtOAc, 8
:
2, v/v). IR (KBr) νmax: 758, 1024, 1185, 1258, 1425, 1587, 1645, 3054, 3438 cm−1. 1H NMR (400 MHz, CDCl3): δ (ppm) = 7.14 (d, J = 5. Hz, 1H), 7.23 (t, J = 7.2 Hz, 1H), 7.34–7.40 (m, 3H), 7.47 (dd, J1 = 16.2 Hz, J2 = 7.8 Hz, 2H), 7.78 (d, J = 5.0 Hz, 1H), 7.85 (d, J = 1.3 Hz, 1H), 7.87 (s, 1H), 8.03–8.07 (m, 2H), 8.46 (d, J = 4.9 Hz, 1H), 10.14 (s, 1H). 13C NMR (100 MHz, CDCl3): δ (ppm) = 112.1, 119.2, 120.7, 120.9, 121.9, 127.2, 128.7, 129.4, 129.5, 131.8, 133.3, 134.7, 135.6, 136.6, 137.1, 137.3, 137.5, 141.1, 148.6, 184.7, 195.0. MS (ESI+) m/z = 383.1. ESI-HRMS calculated for C23H14N2O2S [MH]+: 383.0854, found: 383.0856.
:
EtOAc, 8
:
2, v/v). IR (KBr) νmax: 852, 1042, 1167, 1258, 1402, 1592, 1661, 3052, 3432 cm−1. 1H NMR (400 MHz, CDCl3): δ (ppm) = 7.23–7.29 (m, 4H), 7.34 (t, J = 7.1 Hz, 1H), 7.47 (t, J = 8.2 Hz, 1H), 7.52–7.53 (m, 3H), 7.67 (d, J = 8.4 Hz, 1H), 7.87–7.89 (m, 4H), 8.0 (d, J = 7.8 Hz, 1H), 10.18 (s, 1H). 13C NMR (100 MHz, CDCl3): δ (ppm) = 112.3, 112.6, 119.5, 120.7, 121.1, 121.9, 123.0, 124.5, 127.5, 128.4, 128.5, 128.7, 129.3, 129.6, 131.8, 132.9, 134.3, 136.5, 137.0, 138.5, 141.2, 148.2, 154.7, 183.7, 189.9. MS (ESI+) m/z = 417.1. ESI-HRMS calculated for C27H16N2O3 [MH]+: 417.1239, found: 417.1240.
:
EtOAc, 8
:
2, v/v). IR (KBr) νmax: 712, 1157, 1254, 1401, 1597, 1671, 3020, 3431 cm−1. 1H NMR (400 MHz, CDCl3): δ (ppm) = 7.30–7.35 (m, 3H), 7.43 (t, J = 7.5 Hz, 1H), 7.54–7.58 (m, 3H), 7.62–7.66 (m, 1H), 7.76–7.81 (m, 3H), 7.85 (d, J = 7.7 Hz, 1H), 8.07 (d, J = 4.9 Hz, 1H), 8.10 (d, J = 1.3 Hz, 1H), 10.27 (s, 1H). 13C NMR (100 MHz, CDCl3): δ (ppm) = 113.5, 113.6, 118.7, 122.5, 124.5, 128.3, 129.3, 130.2, 130.3, 130.4, 131.3, 132.0, 132.7, 136.1, 136.4, 137.4, 138.3, 139.4, 139.7, 140.9, 196.7, 198.0. MS (ESI+) m/z = 455.0. ESI-HRMS calculated for C25H15BrN2O2 [MH]+: 455.0395, found: 455.0397.
:
EtOAc, 8
:
2, v/v). IR (KBr) νmax: 728, 1186, 1231, 1445, 1597, 1658, 3028, 3438 cm−1. 1H NMR (400 MHz, CDCl3): δ (ppm) = 7.29–7.35 (m, 3H), 7.39–7.42 (m, 2H), 7.52–7.54 (m, 2H), 7.60–7.64 (m, 1H), 7.76–7.78 (m, 3H), 7.84 (d, J = 7.5 Hz, 1H), 7.91 (d, J = 1.6 Hz, 1H), 8.04 (d, J = 4.9 Hz, 1H), 10.28 (s, 1H). 13C NMR (100 MHz, CDCl3): δ (ppm) = 113.2, 118.7, 121.5, 121.9, 126.3, 128.3, 129.3, 129.5, 130.2, 130.3, 130.3, 130.6, 131.2, 132.7, 136.1, 136.6, 137.4, 138.3, 139.4, 139.5, 140.9, 196.6, 198.0. MS (ESI+) m/z = 411.1. ESI-HRMS calculated for C25H15ClN2O2 [MH]+: 411.0900, found: 411.0904.
:
EtOAc, 8
:
2, v/v). IR (KBr) νmax: 798, 1054, 1263, 1404, 1575, 1668, 1716 3017, 3437 cm−1. 1H NMR (400 MHz, CDCl3): δ (ppm) = 3.83 (s, 3H), 7.27–7.33 (m, 3H), 7.42 (t, J = 7.4 Hz, 1H), 7.49–7.56 (m, 4H), 7.64–7.68 (m, 1H), 7.79 (d, J = 7.5 Hz, 2H), 7.98 (d, J = 7.6 Hz, 1H), 8.05 (d, J = 7.8 Hz, 1H), 8.74 (s, 1H), 10.50 (s, 1H). 13C NMR (100 MHz, CDCl3): δ (ppm) = 52.4, 112.5, 120.9, 121.1, 121.6, 121.9, 128.1, 129.8, 130.2, 130.6, 130.8, 131.6, 131.9, 132.8, 135.6, 136.7, 136.9, 137.3, 139.6, 140.6, 141.5, 165.8, 196.7, 198.0. MS (ESI+) m/z = 435.1. ESI-HRMS calculated for C27H18N2O4 [MH]+: 435.1345, found: 435.1348.
:
EtOAc, 8
:
2, v/v). IR (KBr) νmax: 789, 1059, 1272, 1409, 1571, 1662, 1717 3011, 3439 cm−1. 1H NMR (400 MHz, CDCl3): δ (ppm) = 2.41 (s, 3H), 3.86 (s, 3H), 7.27–7.47 (m, 6H), 7.49–7.54 (m, 2H), 7.77 (d, J = 7.6 Hz, 2H), 8.01–8.07 (m, 2H), 8.76 (s, 1H), 10.47 (s, 1H). 13C NMR (100 MHz, CDCl3): δ (ppm) = 21.7, 52.5, 112.5, 120.8, 121.1, 121.6, 122.0, 128.1, 128.6, 129.8, 130.2, 130.4, 131.3, 131.9, 132.7, 133.7, 135.8, 136.5, 136.6, 137.1, 137.4, 141.2, 141.5, 165.9, 196.9, 197.3. MS (ESI+) m/z = 449.1. ESI-HRMS calculated for C28H20N2O4 [MH]+: 449.1501, found: 449.1505.
:
EtOAc, 8
:
2, v/v). IR (KBr) νmax: 1430, 1467, 1598, 1662, 2925 cm−1. 1H NMR (400 MHz, CDCl3): δ (ppm) = 7.18–7.21 (m, 1H), 7.32 (t, J = 7.7 Hz, 2H), 7.45 (t, J = 7.5 Hz, 1H), 7.51 (d, J = 4.1 Hz, 2H), 7.57–7.61 (m, 1H), 7.66–7.75 (m, 4H), 7.99 (d, J = 7.9 Hz, 1H), 8.22–8.23 (m, 1H). 13C NMR (100 MHz, CDCl3): δ (ppm) = 123.4, 126.6, 128.3, 129.3, 130.2, 130.3, 130.4, 131.2, 132.7, 137.0, 137.4, 139.3, 140.6, 148.6, 153.7, 195.7, 196.6. MS (ESI+) m/z = 288.1. ESI-HRMS calculated for C19H13NO2 [MH]+: 288.1025, found: 288.1030.
:
10, v/v) as eluent to obtain appropriate product 5.
:
EtOAc, 8
:
2, v/v). IR (KBr) νmax: 658, 781, 1045, 1285, 1485, 3085, 3395 cm−1. 1H NMR (400 MHz, CDCl3): δ (ppm) = 7.19–7.25 (m, 1H), 7.48 (d, J = 3.6 Hz, 2H), 7.51–7.54 (m, 4H), 7.75–7.78 (m, 2H), 7.91 (t, J = 7.3 Hz, 1H), 8.01 (d, J = 5.0 Hz, 1H), 8.05–8.10 (m, 2H), 8.61 (d, J = 5.0 Hz, 1H), 10.03 (d, J = 8.4 Hz, 1H), 11.16 (s, 1H). 13C NMR (100 MHz, CDCl3): δ (ppm) = 112.2, 115.9, 120.2, 121.7, 126.6, 126.7, 128.8, 128.9, 129.6, 129.9, 130.3, 130.9, 132.0, 132.6, 133.0, 134.3, 136.2, 136.5, 137.8, 138.7, 140.9, 155.4, 159.6. MS (ESI+) m/z = 373.1. ESI-HRMS calculated for C25H16N4 [MH]+: 373.1453, found: 373.1455.
:
EtOAc, 8
:
2, v/v). IR (KBr) νmax: 667, 768, 1022, 1242, 1461, 3041, 3392 cm−1. 1H NMR (400 MHz, CDCl3): δ (ppm) = 7.23–7.28 (m, 1H), 7.51–7.55 (m, 4H), 7.73 (d, J = 8.2 Hz, 2H), 7.83 (t, J = 7.2 Hz, 1H), 7.96 (t, J = 7.2 Hz, 1H), 8.03–8.07 (m, 2H), 8.13 (d, J = 7.8 Hz, 1H), 8.65 (d, J = 5.0 Hz, 1H), 10.07 (d, J = 8.5 Hz, 1H), 11.11 (s, 1H). 13C NMR (100 MHz, CDCl3): δ (ppm) = 112.2, 116.0, 120.3, 121.5, 121.7, 126.2, 126.6, 128.9, 129.1, 129.2, 131.0, 131.6, 132.3, 132.8, 134.9, 136.0, 136.2, 137.9, 138.5, 140.9, 155.7, 158.6. MS (ESI+) m/z = 407.1. ESI-HRMS calculated for C25H15ClN4 [MH]+: 407.1063, found: 407.1065.
:
EtOAc, 8
:
2, v/v). IR (KBr) νmax: 663, 768, 1012, 1289, 1412, 3082, 3395 cm−1. 1H NMR (400 MHz, CDCl3): δ (ppm) = 7.22–7.26 (m, 1H), 7.49 (d, J = 3.6 Hz, 2H), 7.73 (t, J = 7.9 Hz, 1H), 7.85 (t, J = 7.6 Hz, 1H), 7.97 (t, J = 8.7 Hz, 2H), 8.05 (d, J = 5.0 Hz, 1H), 8.12 (d, J = 7.7 Hz, 2H), 8.39 (d, J = 8.2 Hz, 1H), 8.63–8.66 (m, 2H), 10.09 (d, J = 8.5 Hz, 1H), 11.07 (s, 1H). 13C NMR (100 MHz, CDCl3): δ (ppm) = 112.2, 116.2, 120.4, 121.5, 121.8, 124.5, 125.3, 125.5, 126.3, 126.6, 128.9, 129.6, 129.9, 131.2, 132.7, 133.2, 136.2, 136.3, 138.0, 138.2, 140.9, 148.6, 156.2, 157.4. MS (ESI+) m/z = 418.1. ESI-HRMS calculated for C25H15N5O2 [MH]+: 418.1304, found: 418.1308.
:
EtOAc, 8
:
2, v/v). IR (KBr) νmax: 666, 762, 1068, 1211, 1412, 3015, 3398 cm−1. 1H NMR (400 MHz, CDCl3): δ (ppm) = 6.01 (s, 2H), 6.94 (d, J = 8.3 Hz, 1H), 7.17–7.24 (m, 3H), 7.47 (d, J = 3.8 Hz, 2H), 7.77 (t, J = 7.9 Hz, 1H), 7.86–7.90 (m, 1H), 7.99 (d, J = 5.0 Hz, 1H), 8.08 (dd, J1 = 7.8 Hz, J2 = 4.3 Hz, 2H), 8.59 (d, J = 5.0 Hz, 1H), 9.97 (d, J = 8.4 Hz, 1H), 11.13 (s, 1H). 13C NMR (100 MHz, CDCl3): δ (ppm) = 101.7, 108.6, 110.6, 112.2, 115.8, 120.2, 121.5, 121.7, 124.7, 126.5, 126.6, 128.7, 128.9, 130.3, 130.9, 131.9, 132.6, 136.1, 137.8, 138.7, 140.9, 148.1, 148.9, 155.2, 159.0. MS (ESI+) m/z = 417.1. ESI-HRMS calculated for C26H16N4O2 [MH]+: 417.1352, found: 417.1355.
:
EtOAc, 8
:
2, v/v). IR (KBr) νmax: 668, 768, 1063, 1218, 1409, 3019, 3397 cm−1. 1H NMR (400 MHz, CDCl3): δ (ppm) = 2.50 (s, 3H), 7.22–7.26 (m, 1H), 7.51–7.58 (m, 5H), 7.75–7.78 (m, 3H), 7.84 (s, 1H), 8.05 (d, J = 5.1 Hz, 1H), 8.13 (d, J = 7.8 Hz, 1H), 8.64 (d, J = 5.0 Hz, 1H), 9.95 (d, J = 8.7 Hz, 1H), 11.19 (s, 1H). 13C NMR (100 MHz, CDCl3): δ (ppm) = 112.2, 115.8, 120.2, 121.6, 121.7, 124.9, 125.5, 127.0, 128.8, 128.8, 129.5, 130.3, 130.9, 134.6, 136.2, 136.8, 137.8, 138.9, 140.9, 142.8, 155.4, 159.4. MS (ESI+) m/z = 387.2. ESI-HRMS calculated for C26H18N4 [MH]+: 387.1610, found: 387.1615.
:
EtOAc, 8
:
2, v/v). IR (KBr) νmax: 664, 768, 1068, 1214, 1408, 3017, 3395 cm−1. 1H NMR (400 MHz, CDCl3): δ (ppm) = 3.76 (s, 3H), 7.17–7.21 (m, 1H), 7.29 (d, J = 2.4 Hz, 1H), 7.45–7.53 (m, 6H), 7.75–7.77 (m, 2H), 7.97 (d, J = 5.0 Hz, 1H), 8.07 (d, J = 7.8 Hz, 1H), 8.57 (d, J = 5.0 Hz, 1H), 9.97 (d, J = 9.4 Hz, 1H), 11.21 (s, 1H). 13C NMR (100 MHz, CDCl3): δ (ppm) = 55.7, 112.2, 115.8, 120.2, 121.5, 121.7, 121.9, 123.9, 128.8, 128.8, 129.0, 129.6, 129.7, 130.0, 130.9, 131.2, 136.2, 136.9, 137.8, 138.9, 140.9, 154.9, 159.0. MS (ESI+) m/z = 403.2. ESI-HRMS calculated for C26H18N4O [MH]+: 403.1559, found: 403.1562.
:
EtOAc, 8
:
2, v/v). IR (KBr) νmax: 651, 712, 1012, 1281, 1415, 3084, 3397 cm−1. 1H NMR (400 MHz, CDCl3): δ (ppm) = 7.25 (s, 1H), 7.36–7.42 (m, 3H), 7.52–7.58 (m, 7H), 7.83 (d, J = 5.7 Hz, 2H), 8.06 (d, J = 3.8 Hz, 1H), 8.16 (dd, J1 = 19.3 Hz, J2 = 7.6 Hz, 2H), 8.25 (s, 1H), 8.66 (d, J = 4.3 Hz, 1H), 10.14 (d, J = 8.7 Hz, 1H), 11.21 (s, 1H). 13C NMR (100 MHz, CDCl3): δ (ppm) = 112.2, 115.9, 120.2, 121.5, 121.7, 124.0, 125.6, 127.2, 127.7, 128.7, 128.8, 128.9, 129.3, 129.6, 129.7, 130.3, 130.9, 131.9, 136.2, 136.6, 137.9, 139.6, 140.9, 144.6, 155.3, 159.8. MS (ESI+) m/z = 449.2. ESI-HRMS calculated for C31H20N4 [MH]+: 449.1766, found: 449.1765.
:
EtOAc, 8
:
2, v/v). IR (KBr) νmax: 684, 781, 1015, 1242, 1412, 3042, 3398 cm−1. 1H NMR (400 MHz, CDCl3): δ (ppm) = 7.21–7.28 (m, 1H), 7.52–7.59 (m, 5H), 7.69 (d, J = 5.5 Hz, 1H), 7.95–7.99 (m, 3H), 8.14 (d, J = 7.9 Hz, 1H), 8.66 (d, J = 5.0 Hz, 1H), 10.14 (s, 1H), 11.41 (s, 1H). 13C NMR (100 MHz, CDCl3): δ (ppm) = 112.3, 116.1, 120.3, 121.3, 121.8, 122.5, 128.9, 129.0, 129.6, 129.8, 130.6, 135.1, 135.7, 136.8, 137.2, 137.2, 137.7, 128.3, 141.2, 154.3, 155.2. MS (ESI+) m/z = 379.1. ESI-HRMS calculated for C23H14N4S [MH]+: 379.1017, found: 379.1015.Footnotes |
| † CDRI communication no. 9334. |
| ‡ Electronic supplementary information (ESI) available: Copies of 1H and 13C-spectra of all compounds are provided. See DOI: 10.1039/c6ra11811a |
| This journal is © The Royal Society of Chemistry 2016 |